Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

POS1023 HOW DOES GENDER AFFECT SECUKINUMAB TREATMENT OUTCOMES AND RETENTION RATES IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

(2021) U. Kiltz et al.   ANNALS OF THE RHEUMATIC DISEASES

Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study

(2021) Mehmet Tuncay Duruöz et al.   JOINT BONE SPINE

Understanding differences between men and women with axial spondyloarthritis

(2020) Grace C. Wright et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

(2020) Raphael Micheroli et al.   ANNALS OF THE RHEUMATIC DISEASES

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

(2019) Peter C. Taylor et al.   Journal of Clinical Medicine

Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis

(2019) Florenzo Iannone et al.   RHEUMATOLOGY

Determinants of Patient‐Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association with Gender in 458 Patients from 14 Countries

(2019) Ana‐Maria Orbai et al.   ARTHRITIS CARE & RESEARCH

Gender differences in biologic treatment outcomes—a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers

(2018) Pil Højgaard et al.   RHEUMATOLOGY

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Psoriatic Arthritis

(2017) Christopher T. Ritchlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Multiple Imputation UsingSASSoftware

(2015) Yang Yuan   Journal of Statistical Software

Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA–results from a community based study

(2014) Korosh Hekmat et al.   BMC MUSCULOSKELETAL DISORDERS

Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?

(2014) Lihi Eder et al.   Expert Review of Clinical Immunology

Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)

(2013) Elke Theander et al.   ANNALS OF THE RHEUMATIC DISEASES

Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis

(2012) Lihi Eder et al.   ANNALS OF THE RHEUMATIC DISEASES

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study

(2012) Nienke Lesuis et al.   BMC Medicine

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

(2011) J. A. MARKENSON et al.   JOURNAL OF RHEUMATOLOGY

Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis

(2010) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

(2010) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

(2009) L C Coates et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriatic arthritis

(2009) Dafna D. Gladman   Dermatologic Therapy

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

(2008) Marte Schrumpf Heiberg et al.   ARTHRITIS AND RHEUMATISM